A comprehensive analysis of European competition law and intellectual property law issues affecting the pharmaceutical and biotechnology sectors, offering both theoretical and practical perspectives.
A comprehensive analysis of European competition law and intellectual property law issues affecting the pharmaceutical and biotechnology sectors, offering both theoretical and practical perspectives.
Dr Björn Lundqvist is Associate Professor of EU Competition Law at Copenhagen Business School. He was Head of EU Competition Law at Roschier, Stockholm from 2009 to 2012. He is the author of 'Standardization under EU Competition Rules and US Antitrust Law' (Edward Elgar, 2014); Dr Timo Minssen is a Professor of Biotechnology Law at the University of Copenhagen. He has worked for a Life Science company and for law firms in Sweden and Germany. He has published a number of articles on comparative patent law and EU competition law, including his prize-winning monograph 'Assessing the Inventiveness of Bio-Pharmaceuticals under European and US Patent Law A comparative study with special emphasis on DNA- and protein-related inventions'.; Justin Pierce is a Postdoctoral Researcher at Lund University.
Inhaltsangabe
* Part I: The Pharma and Biotech Business, Framework and Limitations * 1: The Context, Purpose and Limitation of the Book * 2: The Pharma Industry and its Business Strategies * 3: The Legal Framework, Concepts and Basic Principles and the Parallel Trade Regulation * Part II: The Function of Competition Law * 4: Pharma Agreements under Article 101 TFEU * 5: Dominance and Abuse * 6: Pharma Sector-Specific Abusive Conduct * 7: A short comparative analysis of the development under EU Competition law with the US development under the antitrust laws, i.e. Secs. 1 and 2 Sherman Act and Sec. 5 FTC Act. * Part III: Solutions and Reflections * 8: Competition within IPRs the solution to the problems now addressed under Competition law? - The way forward: Future developments, emerging issues and conclusions
* Part I: The Pharma and Biotech Business, Framework and Limitations * 1: The Context, Purpose and Limitation of the Book * 2: The Pharma Industry and its Business Strategies * 3: The Legal Framework, Concepts and Basic Principles and the Parallel Trade Regulation * Part II: The Function of Competition Law * 4: Pharma Agreements under Article 101 TFEU * 5: Dominance and Abuse * 6: Pharma Sector-Specific Abusive Conduct * 7: A short comparative analysis of the development under EU Competition law with the US development under the antitrust laws, i.e. Secs. 1 and 2 Sherman Act and Sec. 5 FTC Act. * Part III: Solutions and Reflections * 8: Competition within IPRs the solution to the problems now addressed under Competition law? - The way forward: Future developments, emerging issues and conclusions
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309
